Findings showed that the combination of insulin and pioglitazone lowered all-cause mortality risk, and this combination therapy exerted beneficial effects on noncardiovascular deaths.
Combination therapy was effective in lowering the HbA1c independent of sex, ethnicity, BMI, or baseline HbA1c.
After analyzing new data, the FDA again warns that the diabetes drug may be associated with an increased risk for bladder cancer.
Bladder cancer risk increases with longer duration of use.
Duration- and dose-response associations for pioglitazone; no correlation for rosiglitazone.
But research reveals association with pancreatic and prostate cancer.
This slideshow reviews drug information for OSENI™ (alogliptin/pioglitazone). Table of Contents Slide 3: Indication, Dosage & AdministrationSlide 6: Use in Specific PopulationsSlide 8: Clinical PharmacologySlide 11: Warnings & PrecautionsSlide 15: Clinical Safety & EfficacySlide 20: Drug Storage & Supply
Emerging evidence links bladder cancer to pelvic radiation therapy, dietary factors, and gene-environment interactions.
Alogliptin, pioglitazone; 12.5mg/15mg, 12.5mg/30mg, 12.5mg/45mg, 25mg/15mg, 25mg/30mg, 25mg/45mg; tabs.
Select the therapeutic use below to view the corresponding drug monograph
Visit the related Resource Center for drug monographs, news, CME and other clinical tools for this drugs’ particular therapeutic area.
The AHA released a statement focusing on the importance of managing cardiovascular risk factors in patients with type 2 diabetes.